Hepatitis A News and Research

RSS

Hepatitis A (formerly known as ''infectious hepatitis'') is an acute infectious disease of the liver caused by the hepatitis A virus (HAV), which is most commonly transmitted by the fecal-oral route via contaminated food or drinking water.

Lifesaving innovation for COVID-19 will increase the already existing racial inequalities

As is the case with most fatal diseases, coronavirus disease (COVID-19) is already taking a disproportionate toll on black Americans and other disadvantaged minorities.

20 May 2020

'Senolytic' therapy blunts liver tumor progression in animal models

"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

20 May 2020

Kids missing measles shots due to coronavirus pandemic

A year ago, the United States saw the highest annual number of measles cases since 1992, with 1,249 cases reported. Of these, 89 percent of the measles patients were unvaccinated or had an unknown vaccination status. Now, fears of another measles outbreak in the country loom as the coronavirus pandemic indirectly is causing a drop in measles vaccinations.

20 May 2020

Does COVID-19 infect peripheral blood cells?

The emergence of the novel coronavirus outbreak in December 2019 was followed by its spread on a global scale unparalleled in the last 100 years. At present, it has claimed over 322,000 lives the world over, with over 4.88 million cases having tested positive.

19 May 2020

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.

19 May 2020

Three FDA-approved drugs can block the replication of COVID-19 virus

Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.

19 May 2020

People with Hepatitis D have up to three times the risk of developing fatal liver cancer

Of all the hepatitis viruses, D is the most poorly known. This small virus, which can only infect people already infected with Hepatitis B, has so far been little studied.

18 May 2020

People infected with hepatitis D are more prone to hepatocellular carcinoma

Of all the hepatitis viruses, D is the most poorly known.This small virus, which can only infect people already infected with Hepatitis B, has so far been little studied.

18 May 2020

Well-known cancer drugs may prevent SARS-CoV-2 viral replication say researchers

Researchers in Frankfurt, Germany, have described cell signaling events that occur when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells and have identified pathways that are essential for the virus to replicate.

17 May 2020

More research is needed to determine if fecal matter spreads COVID-19, say researchers

Early studies show evidence of COVID-19 genetic material in fecal matter, but more work is needed to determine if the virus can be spread through stool, according to a new review paper from a Rice University epidemiologist.

15 May 2020

A 'multi-omics' approach to the development of drugs against COVID-19

A new study published on the preprint server medRxiv* in May 2020 reports a multi-omics approach that could make it easier to develop drugs that are effective against COVID-19.

12 May 2020

Antiviral cocktail may help treat mild COVID-19 patients

The skyrocketing number of cases due to the coronavirus pandemic has taken a massive toll on the health systems in many countries. Since the advent of the coronavirus disease (COVID-19), hundred of research teams are racing to find an effective vaccine and treatment to combat the deadly infection. Now, a team of researchers in Hong Kong suggests that combining three existing antivirals may help treat COVID-19 patients.

12 May 2020

COVID-19 could accelerate activation of dormant tuberculosis (TB)

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).

10 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

Study: Financial incentive can dramatically increase physicians’ training in opioid treatment medication

A new study shows that a financial incentive can dramatically increase the number of emergency department physicians trained to prescribe a potentially life-saving medication that prevents patients from fatal opioid overdose.

6 May 2020

AGA publishes new COVID-19 recommendations for gastroenterologists

AGA has published new expert recommendations in Gastroenterology: AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19.

5 May 2020

COVID-19 progression linked to B cell activation

The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.

4 May 2020